The capstone: what Medicare Advantage actually delivers, for beneficiaries and for taxpayers, read without spin.
Medicare Advantage generates unusually polarized commentary. Industry analyses find it superior; critics find it an overpriced privatization. The evaluation course built the discipline for exactly this situation, so this closing lesson applies it.
What the evidence supports
On quality, the picture is broadly comparable. Most evidence indicates that care quality in MA and traditional Medicare is roughly equivalent overall, with some studies finding MA performs better on particular measures, notably preventive care and avoidable hospital admissions. Those are real advantages and consistent with what a managed, capitated model should produce.
On beneficiary value, MA delivers something real. Supplemental benefits, lower cost sharing, and often zero premiums are genuine, which is a large part of why 55 percent of eligible beneficiaries have chosen it. As Module 4 showed, that coverage is thinner than advertised, but it is not nothing.
On cost to the program, MA is more expensive. MedPAC estimates Medicare pays MA plans about 14 percent more per person than comparable beneficiaries in traditional Medicare in 2026, roughly $76 billion in additional spending, with about $22 billion attributable to higher risk scores.
| Dimension | Defensible verdict |
|---|---|
| Clinical quality | Broadly comparable, some measures favor MA |
| Beneficiary benefits | Real, though thinner than marketed |
| Access | More restricted through networks and prior authorization |
| Cost to Medicare | Substantially higher per person |
Holding both halves
Worth remembering: the two findings that seem contradictory are both true. MA can deliver comparable care and extra benefits to the people enrolled in it and cost the Medicare program more per person than traditional Medicare would have. There is no contradiction, because the extra spending is what funds the extra benefits, plus margin, plus the coding advantage. The real policy question is not whether MA is good or bad but whether the additional public spending buys enough additional value to justify it. That is a judgment about worth, and it should be argued on the numbers rather than settled by slogan.
What to watch
Three things will shape the answer, and all are moving:
- Risk adjustment accuracy. Whether v28 and successor models close the coding gap further.
- Program integrity. Whether RADV audits, and whether extrapolation survives appeal, change plan behavior.
- Quality measurement credibility. Whether Star Ratings stabilize after the litigation, since the bonus rests on them.
The through-line
Medicare Advantage is the largest, most consequential test of everything this curriculum teaches: capitation, risk adjustment, quality measurement tied to payment, utilization management, and delegated provider risk, all at the scale of 35 million people. Reading it honestly, crediting what works and naming what costs, is the same discipline the evaluation course asked for, applied to the highest-stakes case in the field.
Key takeaways
- Quality is broadly comparable with some measures favoring MA, and beneficiary benefits are real if thinner than marketed.
- Access is more restricted, and Medicare pays roughly 14 percent more per person, about $76 billion in 2026.
- Both halves are true; the policy question is whether the added spending buys enough added value, and it should be argued on evidence.
Sources
Check your understanding
What is the most defensible summary of Medicare Advantage's overall record?
The evidence supports a split verdict: real value delivered to enrollees, roughly comparable quality, and payments well above traditional Medicare. Reporting only one half is advocacy rather than analysis.